Sheri Eckert Foundation · Psychedelic Policy Tracker
A rising tide, started in Oregon.
In 2020, Sheri Eckert helped create something that didn't exist anywhere in the world: a state-regulated psychedelic healthcare model, passed by Oregon voters as Measure 109. Five years on, that model has accelerated safe, legal access to psychedelic care faster than any other part of the psychedelic renaissance: three state programs, a wave of state-funded research laws, and more than a hundred bills a year.
And the tide it started is lifting every boat in the harbor.
This tracker follows all of it: every state, the cities, the federal pipeline, the patents, and the world. Updated July 16, 2026.
The map
Every state, ranked by its highest verified policy status.
A functioning regulator outranks a council resolution. This is a map of what's real, not "legal vs. illegal." Tap any state for its model, key bills, sources, and how confident we are in the entry.
POLICY DATA LAST UPDATED · JULY 16, 2026 · 50 states + D.C. · 31 local measures · 29 countries · federal, FDA, patents & the UN. Official program dashboards (Oregon, Colorado) are the systems of record for program numbers.
How to read the landscape
Four lanes, one goal: reaching people who are suffering.
1 · State-regulated access programs
Oregon's template: licensed centers, trained facilitators, adults 21+, safety rules on every dose. Operating in Oregon and Colorado; New Mexico's medical program targets first patients in December 2026. The fastest lane from law to lawful access, at roughly 2–3 years.
2 · State research & clinical-development laws
The 2026 boom is states funding the science themselves: Texas ($50M) and Kentucky ($42M) ibogaine programs, New Jersey's $6M hospital pilot, task forces and "trigger" laws pre-clearing FDA-approved use.
3 · Local decriminalization
Since Denver moved first in 2019, 30+ cities and counties have deprioritized enforcement of personal use. That's politically important protection, but no licensing or care model.
4 · The federal FDA pathway
Essential for nationwide prescribing, and historically slow. No classic psychedelic is FDA-approved yet; the 2024 MDMA rejection proved momentum isn't approval. But the tide has reached Washington: reviews are now accelerating.
The bill ledger
Every principal measure verified this sweep.
Cities & counties
Where cities moved first
Municipal reform is overwhelmingly decriminalization and lowest-priority resolutions (important protection for personal use, but not licensing regimes). measures tracked since Denver's first-in-the-nation ordinance (2019).
The ballot box
Statewide votes
Federal & the pipeline
Federal policy is a drug-development story, with new wind in its sails.
The real-world evidence and public trust built inside state programs helped change the federal weather: an April 2026 executive order directs the FDA to prioritize psychedelic therapies, and priority-review vouchers followed. Here's the full timeline and the clinical pipeline it feeds.
The federal timeline
The clinical pipeline
The patent landscape
Who owns what, and who's keeping the commons open.
Patents shape which companies can profit from psychedelic therapies, and which questions get funded. This is why public-benefit research matters: nobody holds a patent on the questions of access, cost, and equity.
Beyond the U.S.
The tide is global: 29 countries and counting.
Australia prescribes MDMA and psilocybin. Switzerland grants hundreds of medical authorizations a year. Germany and Czechia opened Europe's first doors. The same pattern everywhere: regulated, supervised, medical. It's the model Sheri helped prove.
The global backdrop
The UN system, briefly
All classic psychedelics sit in Schedule I of the 1971 UN Convention: the strictest tier, and the core legal chokepoint on research worldwide. Reform conversations have begun. The details:
The arc
2019 → today: how one measure became a movement.
How we keep this honest
Every entry carries sources and a confidence level. We verify against official state pages, legislature records, and independent trackers (Psychedelic Alpha, UC Berkeley BCSP, Americans for Ibogaine). Fast-moving items are labeled rather than guessed. Spotted something out of date? Tell us, and corrections will ship in the next sweep.
This evidence is what spreads the model
The tide keeps rising because rigorous research inside these programs keeps proving they work. That's what our Research Incubator builds.